Tests a personal exercise plan for people with chronic lymphocytic leukemia on ibrutinib
Studies how exercise affects quality of life in adults with leukemia on ibrutinib.
Plain-language title generated from the registry record
Registry title: Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
Key facts
- Where
- Toulouse, FranceSee the site
Where in France
- Institut Universitaire du Cancer Toulouse - OncopoleToulouse, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen Cilag S.A.S.
- Trial code
- NCT06299540
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL) initiating ibrutinib in a routine clinical practice setting. HRQoL will be measured using functional assessment of cancer therapy - general scale (FACT-G).Read full original descriptionShow less
Benefits of an Individual Physical Activity Intervention on Health-related Quality of Life in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib in Real-life Practice
The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL) initiating ibrutinib in a routine clinical practice setting. HRQoL will be measured using functional assessment of cancer therapy - general scale (FACT-G).
Inclusion: Participants newly treated with ibrutinib for first line or relapsed CLL (treatment is being initiated or has been initiated within the last 8 days as a maximum); Participants agreed to follow the individual physical activity intervention (IPAI); Participants using or having access to a compatible and appropriate electronic device such as smartphone, laptop or tablet; Participants with Internet access at home and email address; Participants agreed to wear a connected watch 24 hours a day for all the duration of the study.
Exclusion: Participants who have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the inclusion visit; Pregnant participants or planning to become pregnant while enrolled in this study; Participants with inability or deemed unsafe to practice physical activity; Participants who are currently involved in an interventional study; Participants with probable difficulties in using the digital tool autonomously.